The seven-amino-acid tail end of angiotensin II, the hormone that raises blood pressure. Enzymes in the body cut it from angiotensin II, and it acts on a different receptor, Mas, with roughly opposite effects: wider blood vessels, less scarring and less cell growth.
Evidence. A hormone the body makes, tested as a drug in small trials since the 2000s and approved nowhere. In 18 adults with advanced cancer, daily injections under the skin set a recommended dose, with a stroke and reversible nerve damage at the dose above it; a 20-person sarcoma trial found no confirmed biomarker effect. Two randomized trials in hospitalized COVID-19 patients, in 343 and 107 people, missed their main goals, the larger one stopping early for futility.
What it’s used for
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
COVID-19 in hospital
TrialNegative: in 343 adults needing oxygen, 5 days of infusions didn’t increase days off oxygen or lower deaths, and the trial stopped early for futility. A 107-patient ICU trial also missed its goal.
Advanced solid tumors
TrialWeak: in 18 adults, one tumor shrank 19% and three more held steady past 3 months, enough to set a recommended dose. A stroke and nerve damage occurred at the dose above it.
Metastatic sarcoma
TrialNegative overall: in 20 adults, the biomarker effect wasn’t confirmed and median time before the cancer grew was 2.7 months, though two vascular sarcomas held steady for 10 and 19 months.
Low blood counts after chemotherapy
TrialMixed: in 20 adults with breast cancer, 100 mcg per kg a day brought fewer episodes of low platelets, anemia and low lymphocytes than filgrastim. No larger trial confirmed it.
High blood pressure
TrialUnproven: short infusions widened kidney vessels in hypertensive adults in one study and did nothing in a forearm study. No trial has tested it as a blood pressure treatment.
Traumatic brain injury
TrialUnknown: a 90-person phase 1/2 trial is recruiting, with completion expected in September 2027. Nothing has been published.
Heart and kidney scarring
AnimalUnproven in people: it reduced scarring in rodent hearts and kidneys, and a related single-chain relaxin peptide did the same. No human trial has measured scarring.
Longevity and general wellness
No studyNo study supports this. Every published human trial treated a specific illness, and the outcome trials were negative.
Trial: tested in people, with the result. Animal: cell or animal studies only. No study: nothing published supports it.
Not approved as a drug in the US, the EU or anywhere else. It holds several FDA orphan drug designations, which are incentives for rare-disease development, not approvals; an EU orphan designation for acute lung injury was granted in 2012 and withdrawn in 2015 at the sponsor’s request. A phase 1/2 trial in traumatic brain injury is recruiting (ClinicalTrials.gov, October 2026). The approved angiotensin drug, angiotensin II (Giapreza), is a different molecule.
US compounding
Never nominated for pharmacy compounding, so it appears on none of FDA’s 503A or 503B bulk substance category lists (503A list updated May 14, 2026).
European Union
No marketing authorization. An EU orphan designation for acute lung injury was granted in October 2012 and withdrawn in November 2015 at the sponsor’s request.
United Kingdom
No marketing authorization (MHRA).
Canada
No marketing authorization (Health Canada).
Australia
No marketing authorization. Angiotensin 1-7 isn’t named in the Poisons Standard (October 2026); angiotensin amide, a different drug, is prescription only.
Sport (WADA 2026)
Likely banned in sportNot named in the 2026 List, and not approved by any health authority, so it falls under S0, non-approved substances, banned at all times. WADA’s 2027 List (in force January 1, 2027) adds “peptides” to S0’s examples, which makes this explicit.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
How it works
Angiotensin 1-7 binds Mas, a receptor found on blood vessels, kidney and heart cells. Acting there, it widens vessels, raises nitric oxide and damps the growth and scarring signals that angiotensin II drives through its own receptor. In cancer trials the measured effect was a drop in placental growth factor, a signal that helps tumors build blood vessels. The body makes it from angiotensin II using ACE2, the same enzyme the COVID-19 virus latches onto.
TrialMainly from studies in people.
Not known
Which of these actions matter clinically is unknown: the trials that measured outcomes were negative, and human infusion studies of blood vessel effects disagree with each other.
Protocol
Trial
Petty 2009
Injections under the skin of 100 to 700 mcg per kg, once daily for 5 days of each 3-week cycle, in 18 adults with advanced cancer. The trial took 400 mcg per kg forward; 700 brought a stroke and reversible nerve damage.
Trial
Savage 2016
20 mg under the skin once daily until the disease progressed, in 20 adults with metastatic sarcoma. Well tolerated, with no need for the planned lower-dose group.
Trial
Self 2023, Martins 2024
IV drip of 0.5 mg per kg once daily for 5 days in 170 hospitalized adults with COVID-19; a separate ICU trial used 5–10 mcg per kg a day continuously for up to 7 days.
Frequency
Once daily in cancer trials; a nonstop drip in hospital trials
Route
Injection under the skin or IV drip (both in clinical trials only)
Cycle
No established cycle. The cancer trials ran 5 days of injections in each 3-week cycle, or daily until the disease progressed; the hospital trials ran 5 to 7 days.
Week 15913172125
No set cycle, shown over 26 weeks
Common protocols
The ways Angiotensin 1-7 is most often run, each tagged with where it comes from.
Phase 1 cancer trial
Trial
Dose
100–700 mcg per kg
How often
Once daily for 5 days, every 3 weeks
How long
Until the disease progressed
18 adults with advanced solid tumors. One tumor shrank 19%, three people held steady over 3 months; 400 mcg per kg was the recommended dose for later trials.
Phase 2 sarcoma trial
Trial
Dose
20 mg
How often
Once daily under the skin
How long
Until the disease progressed
20 adults with metastatic sarcoma. Median time before the cancer grew was 2.7 months and median survival 10.2 months; two vascular sarcomas held steady for 10 and 19 months.
COVID-19 trials
Trial
Dose
0.5 mg per kg daily, or 5–10 mcg per kg a day
How often
Daily IV infusion, or a nonstop drip
How long
5 to 7 days
343 hospitalized adults in the US trial, which stopped early for futility, and 107 ICU patients in Brazil. Neither improved the main outcome.
After chemotherapy
Trial
Dose
Five dose levels, with 100 mcg per kg looking best
How often
Once daily
How long
7 days before chemotherapy, then at least 10 days after each cycle
20 adults with breast cancer, 5 of them given filgrastim instead for comparison. No dose-limiting side effects.
Dosing by body weight
Trial
100–700 mcg/kg. 100 to 700 mcg per kg a day under the skin in the phase 1 cancer trial, with 400 mcg per kg recommended for later trials and dose-limiting events at 700. The COVID-19 trial used 0.5 mg per kg a day by IV drip, and the ICU trial 5–10 mcg per kg a day.
Taking it
Where it goes
Trials injected it under the skin, or ran it into a vein as a drip in hospital. No other route has been tested in people.
If you miss a dose
No published guidance, and no schedule outside trials. In the cancer trials a missed day was simply a missed day; nothing was doubled up.
Blood levels peak, then fall with a half-life of about 25 to 35 minutes at the higher doses tested (Petty 2009).
Trial
Over 1 to 2 three-week cycles, advanced cancer
In the phase 1 trial, 1 of 18 tumors shrank 19% and 3 more people held steady beyond 3 months; levels of a blood vessel growth signal, placental growth factor, fell in those who benefited.
Trial
Over 5 days, hospitalized COVID-19
No improvement in time off oxygen. Deaths within 28 days were 13.5% on the drug and 13.3% on placebo, and the trial stopped early for futility.
Trial
During an infusion into an artery, adults with high blood pressure
Kidney blood flow rose in one study, an effect blunted by a low-salt diet; another study found no change in forearm vessel responses. The findings don’t agree.
Trial
Side effects and what to do
Stroke and reversible nerve damage at the top dose tested (2 of 6 people at 700 mcg per kg)
Both were judged possibly related and set the trial’s ceiling. Sudden weakness, confusion or trouble speaking is an emergency.
Slow heartbeat (one ICU patient, judged possibly related to the drip)
The infusion was stopped. Heart rate was monitored throughout in hospital.
Generally mild side effects otherwise across the cancer trials
The phase 1 trial called the remaining toxicities mild, and the sarcoma trial needed no dose reduction.
Low blood pressure (looked for in the COVID-19 trial)
Rates were similar to placebo there, but it widens blood vessels, so dizziness or fainting is worth watching for.
Unknown with long use
The longest published exposure is months of daily injections in cancer trials, in small numbers of people.
Stop and get medical help
Sudden weakness, numbness, confusion, trouble speaking or seeing, or a severe headache: emergency care, given the strokes seen at the top trial dose. Fainting, or hives with face or throat swelling, also needs urgent help.
Can it cause …?
The side effects people ask about most, answered one by one. Each answer says where it comes from.
Tiredness
TrialFatigue was not singled out in the published trials, which described side effects other than the dose-limiting events as generally mild.
Headache
PrecautionNot reported as a common effect, but a severe headache matters here: strokes occurred at the top dose in the phase 1 cancer trial.
Nausea or vomiting
Not reportedNot reported as a notable side effect in the cancer trials, which called the non-limiting toxicities generally mild.
Dizziness
PrecautionNot reported as common. It widens blood vessels, so light-headedness is a reasoned concern; low blood pressure was as frequent as on placebo in the COVID-19 trial.
Hair loss
No dataNo human data: hair was not reported in any published trial.
Acne, rash or skin changes
No dataNo human data beyond injection-site care; skin effects were not reported in the published trials.
Water retention or swelling
Not reportedNot reported in the published trials. New dialysis, a marker of fluid and kidney trouble, was as common as on placebo in the COVID-19 trial.
Joint or muscle pain
No dataNo human data: joint or muscle pain was not reported in the published trials.
Anxiety, low mood or irritability
No dataNo human data: mood was not measured in the published trials.
Low or high blood sugar
No dataNo human data on blood sugar in people. In rodents the peptide improved insulin sensitivity.
Fast heartbeat or blood pressure changes
TrialOne ICU patient had a serious slow heartbeat judged possibly related to the drip, which was stopped. Low blood pressure was as common as on placebo in the COVID-19 trial.
More hunger
No dataNo human data: appetite was not measured in the published trials.
Liver strain
No dataNo human liver safety data. The cancer trial required near-normal liver tests to enroll, so people with abnormal results were left out.
Kidney problems
TrialNew dialysis was as common as on placebo among 343 hospitalized COVID-19 patients. The cancer trial excluded people with poor kidney function.
Cancer risk
TrialIt was tested as a cancer treatment, not a cause: tumors shrank in a few people and grew in most. No study suggests it causes cancer.
Diarrhea or constipationTrouble sleeping
Not reportedNot reported in the published trials.
Trial: reported in human studies. Precaution: a concern that follows from how it works or from a related drug, not measured. Not reported: studied in people and not reported. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
Who should avoid it
No product label covers angiotensin 1-7, so these come from human studies and from precautions based on how it works. Most important first.
Anyone at high risk of stroke
TrialA grade 4 stroke and reversible cranial nerve damage were the dose-limiting events in the phase 1 cancer trial, at the dose above the one taken forward.
Anyone on blood thinners
TrialThe phase 1 cancer trial excluded people on full-dose anticoagulation, so that combination has never been studied.
Anyone taking an ACE inhibitor or ARB
TrialThe same trial excluded people on these blood pressure drugs, which themselves raise angiotensin 1-7 levels in the body.
Pregnancy or breastfeeding
TrialNo human safety data: the cancer trials excluded pregnant and breastfeeding women, and this peptide rises naturally in pregnancy, which has not been studied as a drug effect.
Anyone with brain metastases
TrialExcluded from the phase 1 trial, which later saw strokes at its top dose.
Anyone relying on product quality
PrecautionNo approved product exists. Trial material was pharmacy-prepared; research powder sold under this name has no regulated standard for identity, purity or sterility.
Interactions
No interaction studies have been published, and no product label exists. ACE inhibitors and ARBs raise the body’s own angiotensin 1-7 levels, and people taking them were excluded from the cancer trials, so the combination is untested.
Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
Special situations
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
Pregnancy
TrialNo human safety data as a drug. The cancer trials excluded pregnant and breastfeeding women; levels of this peptide rise naturally in pregnancy, which is not the same as taking it.
Breastfeeding
TrialNo human data; excluded from the trials, and it isn’t known whether it passes into breast milk.
Kidney problems
TrialThe phase 1 cancer trial required estimated creatinine clearance above 30 mL/min, so poor kidney function wasn’t studied. New dialysis was as common as on placebo in the COVID-19 trial.
Liver problems
TrialThe cancer trial required bilirubin and liver enzymes near normal, so liver disease wasn’t studied.
Older adults
TrialIncluded in the trials without a separate analysis: the stroke trial enrolled up to age 85, and most COVID-19 patients were 31 to 64.
Children and teens
TrialNot approved at any age. A small phase 2 trial in Duchenne muscular dystrophy heart disease enrolled people 16 and older; no trial has studied younger children.
Surgery and anesthesia
TrialA trial in people having heart bypass surgery was stopped after 6 patients. It widens blood vessels, so tell the surgical team about any injected compound.
5 key published human studies, with how many people took part. Animal studies aren’t listed here.
2023343 people
No difference in days off oxygen (adjusted odds ratio 0.88); 28-day deaths 13.5% vs 13.3% on placebo; allergic reactions, new dialysis and low blood pressure were as common as on placebo.
Design
Randomized double-blind placebo-controlled trial (ACTIV-4 Host Tissue), stopped early for futility
Dose
0.5 mg per kg by IV drip once daily for 5 days
Length
28-day main outcome, followed to July 2022
Self et al., JAMA 2023, PMID 37039791
2024107 people
In the randomized part, days off oxygen did not differ (median 19 vs 14, p=0.15); pooling both parts gave 19 vs 14 days (p=0.04). One serious slow heartbeat was judged possibly related.
Design
Seamless phase 1-2 trial: open-label dose step-up, then randomized double-blind placebo-controlled, stopped early for slow recruitment
Dose
5 then 10 mcg per kg a day by continuous IV drip, up to 7 days
Length
28-day main outcome
Martins et al., Ann Intensive Care 2024, PMID 39231898
200918 people
Dose-limiting events at 700 mcg per kg: a grade 4 stroke and grade 3 reversible cranial nerve damage. One tumor shrank 19% and 3 more people held steady beyond 3 months; recommended dose 400 mcg per kg.
Design
Open-label phase 1 dose-escalation trial in cohorts of three
Dose
100 to 700 mcg per kg under the skin, once daily for 5 days of each 3-week cycle
Length
Until the disease progressed
Petty et al., Clin Cancer Res 2009, PMID 19920106
201620 people
Median time before the cancer grew 2.7 months, median survival 10.2 months. The phase 1 biomarker effect was not confirmed, but two vascular sarcomas held steady for 10 and 19 months.
Design
Open-label single-arm phase 2 trial, with a planned lower-dose group that was not needed
Dose
20 mg under the skin once daily
Length
Until the disease progressed
Savage et al., Sarcoma 2016, PMID 27895527
200620 people
No dose-limiting side effects, and fewer adverse events than with filgrastim. At 100 mcg per kg, grade 2–4 low platelets and anemia and grade 3–4 low lymphocytes were less frequent than with filgrastim.
Design
Open-label phase 1/2 dose-escalation study with a filgrastim comparison group (randomization not described)
Dose
Five dose levels under the skin, daily; 100 mcg per kg looked best
Length
7 days before chemotherapy, then at least 10 days after each of three cycles
Rodgers et al., Cancer Chemother Pharmacol 2006, PMID 16096787
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
Phase 1/2NCT06282965
Injections in 90 adults with moderate to severe traumatic brain injury, against saline
Recruiting; completion expected September 2027
Phase 2NCT06135103
TXA127 against placebo in 50 adults after an ischemic stroke
Status listed as unknown; completion was planned for September 2025
Phase 2NCT06013839
TXA127 in 10 people aged 16 and older with Duchenne muscular dystrophy heart disease
Status listed as unknown; completion was planned for December 2024
Phase 2NCT03159988
Angiotensin-(1-7) with memory training for thinking problems in heart failure
Suspended; 6 enrolled, listed completion June 2026
About 500 people have received it in published trials: two COVID-19 trials of 343 and 107 patients, both missing their main goals, and cancer trials of 18, 20 and 20 people. The cancer work was open-label with no control group. Nothing has been tested for more than a few months, no trial has studied healthy people, and the vascular infusion studies in adults disagree.
How it’s supplied
Cancer trials injected 100–700 mcg per kg daily under the skin, or 20 mg daily; hospital trials used IV drips. Not sold as a medicine. Given in trials only: a daily injection under the skin for 5–10 days per cycle, or a nonstop IV drip for up to 7 days in hospital. It’s available only in clinical trials, so the calculator and dose log don’t apply.
Datasheet
Half-life
about 25 to 35 minutesTrialMean half-life 0.42 to 0.61 hour across the three highest dose levels after injection under the skin in adults with advanced cancer, with peak blood levels at about 1 hour.
Type
Peptide, 7 amino acids
Molecular weight
899 g/mol
Formula
C41H62N12O11
Sequence
DRVYIHP
Storage before use
Freezer (−20 °C) for long-term storage of the powder, kept dry and dark.
After mixing or opening
Fridge (2–8 °C), used soon after mixing; one public reference says within 24 hours.
Half-life: Petty et al., Clin Cancer Res 2009, PMID 19920106
Molecule: PubChem CID 123805; FDA GSRS UNII IJ3FUK8MOF (talfirastide, CAS 51833-78-4, DrugBank DB11720, ChEMBL CHEMBL3545347). Residues 1–7 of angiotensin II, which is the same chain plus phenylalanine. Weight calculated from the formula; the acetate salt has its own record
Storage:Community Common research-peptide practice; no approved label exists for this peptide
No approved product. Trial material was pharmacy-prepared; the acetate salt has its own FDA substance record, so a milligram of powder holds slightly less peptide than a milligram of free base. Research powder has no regulated identity or sterility standard.
Cautions
Not approved anywhere. Every human dose comes from a trial, where staff prepared and gave it and watched for side effects.
At 700 mcg per kg a day in the phase 1 cancer trial, one patient had multiple strokes and another reversible nerve damage affecting the tongue; both were judged possibly related.
It leaves the blood in well under an hour, so trials used daily injections or a nonstop drip, not weekly dosing.
The trials that measured outcomes were negative: no benefit in two COVID-19 trials, and no confirmed biomarker effect in sarcoma.
Likely banned in sport: it isn’t named on the 2026 Prohibited List, so it falls under S0, non-approved substances.
Questions
What is angiotensin 1-7?
The seven-amino-acid tail end of angiotensin II, the hormone that raises blood pressure. Enzymes in the body cut it from angiotensin II, and it acts on a different receptor, Mas, with roughly opposite effects: wider blood vessels, less scarring and less cell growth.
How does angiotensin 1-7 work?
Angiotensin 1-7 binds Mas, a receptor found on blood vessels, kidney and heart cells. Acting there, it widens vessels, raises nitric oxide and damps the growth and scarring signals that angiotensin II drives through its own receptor. In cancer trials the measured effect was a drop in placental growth factor, a signal that helps tumors build blood vessels. The body makes it from angiotensin II using ACE2, the same enzyme the COVID-19 virus latches onto. Which of these actions matter clinically is unknown: the trials that measured outcomes were negative, and human infusion studies of blood vessel effects disagree with each other.
Is angiotensin 1-7 FDA-approved?
Not approved as a drug in the US, the EU or anywhere else. It holds several FDA orphan drug designations, which are incentives for rare-disease development, not approvals; an EU orphan designation for acute lung injury was granted in 2012 and withdrawn in 2015 at the sponsor’s request. A phase 1/2 trial in traumatic brain injury is recruiting (ClinicalTrials.gov, October 2026). The approved angiotensin drug, angiotensin II (Giapreza), is a different molecule. Never nominated for pharmacy compounding, so it appears on none of FDA’s 503A or 503B bulk substance category lists (503A list updated May 14, 2026).
What is the usual angiotensin 1-7 dose?
From human studies (Petty 2009): Injections under the skin of 100 to 700 mcg per kg, once daily for 5 days of each 3-week cycle, in 18 adults with advanced cancer. The trial took 400 mcg per kg forward; 700 brought a stroke and reversible nerve damage. Savage 2016: 20 mg under the skin once daily until the disease progressed, in 20 adults with metastatic sarcoma. Well tolerated, with no need for the planned lower-dose group. These are the amounts sources reference, not recommendations.
How is angiotensin 1-7 given?
Given in trials only: a daily injection under the skin for 5–10 days per cycle, or a nonstop IV drip for up to 7 days in hospital. It isn’t sold: it’s available only in clinical trials.
Who should avoid angiotensin 1-7?
No product label covers angiotensin 1-7, so these come from human studies and from precautions based on how it works. Anyone at high risk of stroke: A grade 4 stroke and reversible cranial nerve damage were the dose-limiting events in the phase 1 cancer trial, at the dose above the one taken forward. Anyone on blood thinners: The phase 1 cancer trial excluded people on full-dose anticoagulation, so that combination has never been studied. Anyone taking an ACE inhibitor or ARB: The same trial excluded people on these blood pressure drugs, which themselves raise angiotensin 1-7 levels in the body. The “Who should avoid it” section lists 3 more groups.
What is the half-life of angiotensin 1-7?
About 25 to 35 minutes, measured in human studies. Mean half-life 0.42 to 0.61 hour across the three highest dose levels after injection under the skin in adults with advanced cancer, with peak blood levels at about 1 hour.
How should angiotensin 1-7 be stored?
Freezer (−20 °C) for long-term storage of the powder, kept dry and dark. Fridge (2–8 °C), used soon after mixing; one public reference says within 24 hours. This is common practice; no product label covers it.
Is angiotensin 1-7 banned in sport?
Probably. Not named in the 2026 List, and not approved by any health authority, so it falls under S0, non-approved substances, banned at all times. WADA’s 2027 List (in force January 1, 2027) adds “peptides” to S0’s examples, which makes this explicit.
Has angiotensin 1-7 been studied in people?
Yes. The human studies section lists 5 published studies. The largest, from 2023, included 343 people. No difference in days off oxygen (adjusted odds ratio 0.88); 28-day deaths 13.5% vs 13.3% on placebo; allergic reactions, new dialysis and low blood pressure were as common as on placebo.
How long has angiotensin 1-7 been studied in people?
Trial Months, in small cancer trials where daily injections continued until the disease progressed; the hospital trials ran 5 to 7 days.
Does angiotensin 1-7 come in other forms, like a pill or nasal spray?
Trial Trials used injection under the skin and IV drips. One public reference mentions oral research formulations; no oral, nasal or skin product has been tested in people.
Can you drink alcohol while taking angiotensin 1-7?
No study No data. No trial examined alcohol, and none of the published trials mentions it.
Can angiotensin 1-7 be taken with semaglutide or tirzepatide?
Precaution No study has combined them. Both can lower blood pressure, so in theory the effects could add up, but nothing has been measured.
What happens if you take too much angiotensin 1-7?
Trial No label. In the phase 1 cancer trial, 700 mcg per kg a day caused a stroke in one patient and reversible nerve damage in another. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
Sources
Petty et al., phase 1 and pharmacokinetic study of angiotensin-(1-7) in 18 adults with advanced solid tumors (Clin Cancer Res 2009) PMID 19920106
Savage et al., phase 2 trial of angiotensin-(1-7) in 20 adults with metastatic sarcoma (Sarcoma 2016) PMID 27895527
Self et al., TXA-127 (synthetic angiotensin 1-7) in 343 adults hospitalized with COVID-19, ACTIV-4 Host Tissue (JAMA 2023) PMID 37039791
Martins et al., angiotensin-(1-7) infusion in 107 ICU patients with COVID-19, seamless phase 1-2 trial (Ann Intensive Care 2024) PMID 39231898
Rodgers et al., phase 1/2 dose-escalation study after chemotherapy in 20 patients with breast cancer (Cancer Chemother Pharmacol 2006) PMID 16096787
FDA Global Substance Registration System record for talfirastide (UNII IJ3FUK8MOF, CAS 51833-78-4); ClinicalTrials.gov searches (October 9, 2026)
For the protocol details
van Twist et al., angiotensin-(1-7) infusion and kidney blood flow in hypertensive adults (Hypertension 2013) PMID 23918750
For how it works, who should avoid it and the limits of the evidence
Wilsdorf et al., angiotensin-(1-7) did not change forearm vessel responses to bradykinin (Hypertension 2001) PMID 11304515
Petty et al., reverse translation linking angiotensin-(1-7) activity to HIF-1α in vascular sarcoma (BMC Cancer 2012) PMID 22963500
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US
Ueda et al., angiotensin-(1-7) potentiates bradykinin-induced vasodilation in people (J Hypertens 2001) PMID 11677365
ClinicalTrials.gov records NCT06282965, NCT06135103, NCT06013839, NCT03159988, NCT00471562, NCT01553539, NCT03252093 (checked October 9, 2026)
FDA GSRS record for talfirastide (UNII IJ3FUK8MOF); EMA orphan designation EU/3/12/1047; Australian Poisons Standard, October 2026